Here's a deep dive into the details of the European Falsified Medicines Directive regulation and requirements for pharma manufacturers and non-manufacturers.

In an era where sustainability is a driving force for change, Systech empowers companies to make responsible choices, reduce waste and enhance transparency.

With the United States being far and away the largest pharmaceutical market in the world, complying with necessary regulations is critical for the industry.

Systech announced recently that it joined the National Association of Boards of Pharmacy (NABP) Interoperable Partner Program, Pulse by NABP. This is important news as both Systech and NABP want to ensure that pharmacies and dispensers are ready for DSCSA (Drug Supply Chain Security Act) compliance this November. Though a stabilization period has been granted by the FDA, the November 27, 2023 date is still the legal target for the industry. 

This extension is pivotal in addressing evolving challenges and further fortifying the integrity of the pharmaceutical supply chain.

In the realm of taxation and revenue collection, governments face numerous challenges in ensuring compliance, minimizing tax evasion, and combating the illicit trade of goods.

Don’t misconstrue that the DSCSA implementation is being delayed—it isn’t.

As part of the FDA’s Drug Quality and Security Act, one key rationale for the Drug Supply Security Act (DSCSA) was to protect US patients from receiving counterfeit or illegitimate medications. Everything the industry is doing to connect manufacturers, wholesalers and dispensers to create an interoperable supply chain is all about patient safety.

In the rapidly evolving landscape of pharmaceuticals, maintaining regulatory compliance is paramount for pharmacies. The Drug Supply Chain Security Act (DSCSA) aims to enhance patient safety by establishing a secure supply chain for prescription drugs.